Efficacy News and Research

RSS

Columbia scientists discover new way to alleviate chronic pain

Columbia scientists working to combat injury-related depression, substance abuse and suicide due to unremitting, persistent pain may have discovered a new way of treating that pain: a powerful analgesic dubbed N60 that leads to neither tolerance nor addiction.

16 Jul 2010

Noscira presents results of Nypta Phase IIa clinical trial for AD at ICAD 2010

Noscira, the Grupo Zeltia (ZEL.MC) subsidiary specialized in researching and developing drugs for treating neurodegenerative diseases, presented the results of a Phase IIa clinical trial of Nypta(R) (Tideglusib) on Alzheimer's disease (AD) at the International Conference on Alzheimer's Disease (ICAD), held in Honolulu (Hawaii) from July 10-15, 2010.

16 Jul 2010

Cubist Pharmaceuticals total net revenues for second-quarter 2010 increase 29%

Cubist Pharmaceuticals, Inc. today announced results for the second quarter ended June 30, 2010.

16 Jul 2010

Rapid weight loss the best: Study

Researchers have now shown that the best way to lose weight is to lose a lot of it at once contrary to popular belief even among doctors that weight should be lost slowly.

15 Jul 2010

QR Pharma to present positive clinical data from mechanism of action study in MCI at ICAD 2010

QR Pharma, Inc., a developer of novel drugs to treat Alzheimer's disease (AD), is presenting a poster today on positive clinical data from its recent mechanism of action study in mild cognitive impaired (MCI) patients at the International Congress on Alzheimer's Disease (ICAD 2010).

15 Jul 2010

Access announces agreement to develop oral formulation of proprietary injectable drugs

Access Pharmaceuticals, Inc., announced today that it has entered into a pre-licensing feasibility agreement with a leading biotechnology company to develop an oral formulation of its currently-marketed, proprietary injectable drugs. Access will utilize its proprietary Cobalamin Oral Drug Delivery Technology to develop oral formulations of the drug for pre-clinical testing.

15 Jul 2010

Activities of TAT fully consolidated into Geron

Geron Corporation today announced that the activities of TA Therapeutics, its joint venture with Hong Kong University of Science and Technology, are being fully consolidated into Geron.

15 Jul 2010

Plexxikon announces promising preclinical data of PLX3397

Plexxikon Inc. today announced promising preclinical data from in vivo Alzheimer's Disease studies demonstrating a dramatic reduction in activated microglia in the brains of very old (22 months) 3xTG-AD mice, a triple transgenic model for Alzheimer's Disease. This reduction of activated microglia led to significantly improved learning in the treated group.

15 Jul 2010

Research addresses challenges for future HIV vaccine

On the eve of the world's biggest AIDS conference this month in Austria, a new research review shows many people wouldn't get inoculated against HIV even if a vaccine was developed.

15 Jul 2010

Medical standard of care triggers biological responses in brain that can fuel tumor cell survival: Researchers

The medical standard of care - comprised of surgery, radiation and chemotherapy - for the most common form of brain cancer triggers a number of biological responses that may actually feed the energy metabolism that supports the disease, according to Boston College researchers writing in the journal Lancet Oncology.

15 Jul 2010

Variations in quality of illegal Class B drug mephedrone could risk safety of users

Pharmaceutical scientists have discovered that the recently reclassified drug mephedrone varies in quality so much that users could be at risk of overdosing. Six samples were tested in the University of Sunderland's labs by Dr John Lough and his team, and although impurities levels were low, three samples revealed various particle size and crystalline form, which means that the drug is more likely to vary in its affect and safety on the user.

15 Jul 2010

New Cystex Liquid Cranberry Complex with Proantinox reduces incidence of UTIs in women: Study

A new study being published in the journal Urology shows that Proantinox, a proprietary cranberry-based blend used successfully in hospitals and long-term care facilities as UTI-Stat, and now available directly to consumers as new Cystex Liquid Cranberry Complex with Proantinox, is safe and effective in significantly reducing the incidence of UTIs in women at risk for recurring infections.

15 Jul 2010

AMS reports positive results from clinical trial of MiniArc Single-Incision Sling System for SUI

American Medical Systems® (AMS), a leading provider of world-class devices and therapies for both male and female pelvic health, today announced results of a prospective, multi-center study on their market leading MiniArc Single-Incision Sling System for female stress urinary incontinence (SUI). The study concludes that MiniArc efficacy rates for negative cough stress test (CST) and 1-hr Pad Weight Test (PWT) at 12 months were 90.6 percent and 84.5 percent, respectively.

15 Jul 2010

Evotec to acquire DeveloGen

Evotec AG today announced the signing of a definitive agreement to acquire DeveloGen, a biopharmaceutical company engaged in the discovery of novel therapeutic approaches for the treatment of metabolic and endocrine disorders, for up to €14m in shares plus performance-related deferred payments (earn-out).

15 Jul 2010

Amorfix grants Biogen Idec exclusive worldwide rights to lead ALS monoclonal antibodies

Amorfix Life Sciences Ltd. today announced that it has entered into a licensing agreement granting Biogen Idec exclusive worldwide rights to Amorfix's lead amyotrophic lateral sclerosis (ALS) monoclonal antibodies. The antibodies have shown efficacy in animal models of ALS and Biogen Idec will now, at its expense, complete the development and prepare for clinical trials.

15 Jul 2010

Starpharma gets FDA nod to start phase 2 bacterial vaginosis study for VivaGel

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced it had received clearance from the US Food and Drug Administration (FDA) to commence a phase 2 study to investigate VivaGel® for the treatment of bacterial vaginosis (BV).

15 Jul 2010

Hendra virus treatment to be ready in a few months

Of the dozen people who were exposed to a horse infected with the Hendra virus, 11 have been cleared of the infection by repeated tests on Queensland's Sunshine Coast. These 12 people had first come into contact with the infected horse at Tewantin in May and have since then been subjected to testing to rule out infection with the deadly virus. It is expected that the 12th person will also be cleared soon. Quarantine restrictions were also lifted last month.

14 Jul 2010

Aastrom commences extension study for control patients from Phase 2 IMPACT-DCM clinical trial

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced the initiation of an extension study for control patients from the company's ongoing open-label Phase 2 IMPACT-DCM clinical trial in patients with dilated cardiomyopathy (DCM).

14 Jul 2010

SANUWAVE Health introduces orthoPACE device in Europe

SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, reports the European launch of the orthoPACE device intended for use in orthopedic, trauma and sports medicine indications following CE mark approval last month.

14 Jul 2010

BioInvent reports net revenues of SEK 63.1M for January - June 2010 period

BioInvent reached an important milestone when the results of a phase II trial of TB-402 following orthopaedic surgery, were reported in May. The data showed that TB-402 is statistically better at preventing thrombosis than enoxaparin, the current standard treatment. Supported by these good results, BioInvent and the company's partner, ThromboGenics, will now prioritise securing a development partner for the programme to ensure that the necessary resources is in place to take the product candidate to the market.

14 Jul 2010

Efficacy News and Research

Columbia scientists discover new way to alleviate chronic pain

Noscira presents results of Nypta Phase IIa clinical trial for AD at ICAD 2010

Cubist Pharmaceuticals total net revenues for second-quarter 2010 increase 29%

Rapid weight loss the best: Study

QR Pharma to present positive clinical data from mechanism of action study in MCI at ICAD 2010

Access announces agreement to develop oral formulation of proprietary injectable drugs

Activities of TAT fully consolidated into Geron

Plexxikon announces promising preclinical data of PLX3397

Research addresses challenges for future HIV vaccine

Medical standard of care triggers biological responses in brain that can fuel tumor cell survival: Researchers

Variations in quality of illegal Class B drug mephedrone could risk safety of users

New Cystex Liquid Cranberry Complex with Proantinox reduces incidence of UTIs in women: Study

AMS reports positive results from clinical trial of MiniArc Single-Incision Sling System for SUI

Evotec to acquire DeveloGen

Amorfix grants Biogen Idec exclusive worldwide rights to lead ALS monoclonal antibodies

Starpharma gets FDA nod to start phase 2 bacterial vaginosis study for VivaGel

Hendra virus treatment to be ready in a few months

Aastrom commences extension study for control patients from Phase 2 IMPACT-DCM clinical trial

SANUWAVE Health introduces orthoPACE device in Europe

BioInvent reports net revenues of SEK 63.1M for January - June 2010 period

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News